Over-expression of Activin-βC is associated with murine and human prostate disease

Edward C. Ottley, Karen L. Reader, Kailun Lee, Francesco E. Marino, Helen D. Nicholson, Gail P. Risbridger, Elspeth Gold

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Activins are members of the TGF-β superfamily and have been linked to prostate cancer. There are four mammalian activin subunits (βA, βB, βC, and βE) that dimerize to form functional proteins. The role of activin-A (βA-βA) has been relatively well characterized and has been shown to generally inhibit growth in the prostate. In contrast, little is known about the biological function of the βC and βE subunits. Previous work indicated activin-C (βC-βC) to be an antagonist of activin-A. This is important because resistance to activin-A growth inhibition occurs during prostate cancer progression. This paradox is not currently well understood. Hence, we hypothesize that local expression of the activin-βC subunit antagonizes activin-A-dependent growth inhibition and represents a key factor contributing to acquired insensitivity to activin-A observed in prostate cancer progression. To test our hypothesis, we characterized the ventral prostate lobes of 9-month-old transgenic mice over-expressing activin-βC and examined the expression of activin-βA, activin-βC, and the activin intracellular signaling factor, Smad-2, in human prostate diseases. Prostate epithelial cell hyperplasia, low-grade prostatic intraepithelial neoplasia (PIN) lesions, alterations in cell proliferation, and reduced Smad-2 nuclear localization were evident in mice over-expressing activin-βC. Increased activin-βA and -βC subunit immunoreactive scores and decreased Smad-2 nuclear localization were also evident in human prostate cancer. This study suggests that over-expression of activin-βC is associated with murine and human prostate pathologies. We conclude that the activin-βC subunit may have therapeutic and/or diagnostic implications in human prostate disease.

Original languageEnglish
Pages (from-to)100-107
Number of pages8
JournalHormones and Cancer
Volume8
Issue number2
DOIs
Publication statusPublished - Apr 2017

Cite this

Ottley, E. C., Reader, K. L., Lee, K., Marino, F. E., Nicholson, H. D., Risbridger, G. P., & Gold, E. (2017). Over-expression of Activin-βC is associated with murine and human prostate disease. Hormones and Cancer, 8(2), 100-107. https://doi.org/10.1007/s12672-017-0283-8
Ottley, Edward C. ; Reader, Karen L. ; Lee, Kailun ; Marino, Francesco E. ; Nicholson, Helen D. ; Risbridger, Gail P. ; Gold, Elspeth. / Over-expression of Activin-βC is associated with murine and human prostate disease. In: Hormones and Cancer. 2017 ; Vol. 8, No. 2. pp. 100-107.
@article{7b747c235dda4ee497cd34bc3ded927a,
title = "Over-expression of Activin-βC is associated with murine and human prostate disease",
abstract = "Activins are members of the TGF-β superfamily and have been linked to prostate cancer. There are four mammalian activin subunits (βA, βB, βC, and βE) that dimerize to form functional proteins. The role of activin-A (βA-βA) has been relatively well characterized and has been shown to generally inhibit growth in the prostate. In contrast, little is known about the biological function of the βC and βE subunits. Previous work indicated activin-C (βC-βC) to be an antagonist of activin-A. This is important because resistance to activin-A growth inhibition occurs during prostate cancer progression. This paradox is not currently well understood. Hence, we hypothesize that local expression of the activin-βC subunit antagonizes activin-A-dependent growth inhibition and represents a key factor contributing to acquired insensitivity to activin-A observed in prostate cancer progression. To test our hypothesis, we characterized the ventral prostate lobes of 9-month-old transgenic mice over-expressing activin-βC and examined the expression of activin-βA, activin-βC, and the activin intracellular signaling factor, Smad-2, in human prostate diseases. Prostate epithelial cell hyperplasia, low-grade prostatic intraepithelial neoplasia (PIN) lesions, alterations in cell proliferation, and reduced Smad-2 nuclear localization were evident in mice over-expressing activin-βC. Increased activin-βA and -βC subunit immunoreactive scores and decreased Smad-2 nuclear localization were also evident in human prostate cancer. This study suggests that over-expression of activin-βC is associated with murine and human prostate pathologies. We conclude that the activin-βC subunit may have therapeutic and/or diagnostic implications in human prostate disease.",
author = "Ottley, {Edward C.} and Reader, {Karen L.} and Kailun Lee and Marino, {Francesco E.} and Nicholson, {Helen D.} and Risbridger, {Gail P.} and Elspeth Gold",
year = "2017",
month = "4",
doi = "10.1007/s12672-017-0283-8",
language = "English",
volume = "8",
pages = "100--107",
journal = "Hormones and Cancer",
issn = "1868-8497",
publisher = "Endocrine Society",
number = "2",

}

Ottley, EC, Reader, KL, Lee, K, Marino, FE, Nicholson, HD, Risbridger, GP & Gold, E 2017, 'Over-expression of Activin-βC is associated with murine and human prostate disease' Hormones and Cancer, vol. 8, no. 2, pp. 100-107. https://doi.org/10.1007/s12672-017-0283-8

Over-expression of Activin-βC is associated with murine and human prostate disease. / Ottley, Edward C.; Reader, Karen L.; Lee, Kailun; Marino, Francesco E.; Nicholson, Helen D.; Risbridger, Gail P.; Gold, Elspeth.

In: Hormones and Cancer, Vol. 8, No. 2, 04.2017, p. 100-107.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Over-expression of Activin-βC is associated with murine and human prostate disease

AU - Ottley, Edward C.

AU - Reader, Karen L.

AU - Lee, Kailun

AU - Marino, Francesco E.

AU - Nicholson, Helen D.

AU - Risbridger, Gail P.

AU - Gold, Elspeth

PY - 2017/4

Y1 - 2017/4

N2 - Activins are members of the TGF-β superfamily and have been linked to prostate cancer. There are four mammalian activin subunits (βA, βB, βC, and βE) that dimerize to form functional proteins. The role of activin-A (βA-βA) has been relatively well characterized and has been shown to generally inhibit growth in the prostate. In contrast, little is known about the biological function of the βC and βE subunits. Previous work indicated activin-C (βC-βC) to be an antagonist of activin-A. This is important because resistance to activin-A growth inhibition occurs during prostate cancer progression. This paradox is not currently well understood. Hence, we hypothesize that local expression of the activin-βC subunit antagonizes activin-A-dependent growth inhibition and represents a key factor contributing to acquired insensitivity to activin-A observed in prostate cancer progression. To test our hypothesis, we characterized the ventral prostate lobes of 9-month-old transgenic mice over-expressing activin-βC and examined the expression of activin-βA, activin-βC, and the activin intracellular signaling factor, Smad-2, in human prostate diseases. Prostate epithelial cell hyperplasia, low-grade prostatic intraepithelial neoplasia (PIN) lesions, alterations in cell proliferation, and reduced Smad-2 nuclear localization were evident in mice over-expressing activin-βC. Increased activin-βA and -βC subunit immunoreactive scores and decreased Smad-2 nuclear localization were also evident in human prostate cancer. This study suggests that over-expression of activin-βC is associated with murine and human prostate pathologies. We conclude that the activin-βC subunit may have therapeutic and/or diagnostic implications in human prostate disease.

AB - Activins are members of the TGF-β superfamily and have been linked to prostate cancer. There are four mammalian activin subunits (βA, βB, βC, and βE) that dimerize to form functional proteins. The role of activin-A (βA-βA) has been relatively well characterized and has been shown to generally inhibit growth in the prostate. In contrast, little is known about the biological function of the βC and βE subunits. Previous work indicated activin-C (βC-βC) to be an antagonist of activin-A. This is important because resistance to activin-A growth inhibition occurs during prostate cancer progression. This paradox is not currently well understood. Hence, we hypothesize that local expression of the activin-βC subunit antagonizes activin-A-dependent growth inhibition and represents a key factor contributing to acquired insensitivity to activin-A observed in prostate cancer progression. To test our hypothesis, we characterized the ventral prostate lobes of 9-month-old transgenic mice over-expressing activin-βC and examined the expression of activin-βA, activin-βC, and the activin intracellular signaling factor, Smad-2, in human prostate diseases. Prostate epithelial cell hyperplasia, low-grade prostatic intraepithelial neoplasia (PIN) lesions, alterations in cell proliferation, and reduced Smad-2 nuclear localization were evident in mice over-expressing activin-βC. Increased activin-βA and -βC subunit immunoreactive scores and decreased Smad-2 nuclear localization were also evident in human prostate cancer. This study suggests that over-expression of activin-βC is associated with murine and human prostate pathologies. We conclude that the activin-βC subunit may have therapeutic and/or diagnostic implications in human prostate disease.

UR - http://www.scopus.com/inward/record.url?scp=85010739599&partnerID=8YFLogxK

U2 - 10.1007/s12672-017-0283-8

DO - 10.1007/s12672-017-0283-8

M3 - Article

VL - 8

SP - 100

EP - 107

JO - Hormones and Cancer

JF - Hormones and Cancer

SN - 1868-8497

IS - 2

ER -